Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540297 | 1.00 | HDAC8 (0.71) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5909363 | 0.87 | HDAC8 (0.83) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27668893 | 0.86 | SMN1; SMN2 (0.70) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28744940 | 0.86 | HDAC8 (0.69) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24931248 | 0.85 | SMN1; SMN2 (0.89) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12200279 | 0.84 | MEN1 (0.87) | SMN1; SMN2MEN1KMT2AKCNK3KCNK9 | |
| SCHEMBL21653856 | 0.84 | SMN1; SMN2 (0.79) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30929655 | 0.83 | HDAC6 (1.00) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5242529 | 0.83 | HDAC6 (1.00) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15328144 | 0.82 | HDAC8 (0.65) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11066749-B2 | Corrosion inhibition of HCL treatment fluids with environmentally compatible solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-07-20 | — | — | US | claimed |
| US-20200173034-A1 | Corrosion Inhibition of HCL Treatment Fluids with Environmentally Compatible Solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-10604850-B2 | Corrosion inhibition of HCL treatment fluids with environmentally compatible solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2020-03-31 | — | — | US | claimed |
| US-20180127882-A1 | Corrosion Inhibition of HCL Treatment Fluids with Environmentally Compatible Solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2018-05-10 | — | — | US | claimed |
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | claimed |
| EP-3154964-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | The University of Kansas (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2016190865-A1 | CORROSION INHIBITION OF HCL TREATMENT FLUIDS WITH ENVIRONMENTALLY COMPATIBLE SOLVENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2015192099-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-12-17 | — | — | WO | claimed |
| EP-2646600-A1 | CORROSION INHIBITOR COMPOSITIONS COMPRISING REACTION PRODUCTS OF ALDEHYDES AND AMIDES AND RELATED METHODS | Halliburton Energy Services, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| US-8361937-B2 | Corrosion inhibitor compositions comprising reaction products of aldehydes and amides and related methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012072986-A1 | CORROSION INHIBITOR COMPOSITIONS COMPRISING REACTION PRODUCTS OF ALDEHYDES AND AMIDES AND RELATED METHODS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142563-A1 | Corrosion Inhibitor Compositions Comprising Reaction Products of Aldehydes and Amides and Related Methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4074697-B1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | SAMJIN PHARM CO LTD (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-3959269-A | TRANQUILIZERS, SEDATIVES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | HDAC8 677/4885HDAC6 581/4885SMN1; SMN2 2457/4885 |
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HDAC8 131/4885HDAC6 27/4885SMN1; SMN2 4736/4885 |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | PTK2, CTTN, ADGRF1 | HDAC8 2084/4885HDAC6 1678/4885SMN1; SMN2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.